The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).
Guru Sonpavde
Research Funding - Sanofi
Menaka Bhor
No relevant relationships to disclose
Daniel Hennessy
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Debajyoti Bhowmik
Employment or Leadership Position - McKesson
Liji Shen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Other Remuneration - Sanofi
Ian D. Schnadig
No relevant relationships to disclose